One of the most complex and important issues involving antitrust and intellectual property involves agreements by which brand-name drug firms pay generics to stay off the market. In its Actavis decision (and in contrast to multiple appellate court decisions), the Supreme Court affirmed that this behavior can violate the antitrust laws. This post for IP Watchdog summarizes the decision and explains why it was so important.